International Vaccine Institute

The International Vaccine Institute (IVI) is an independent international organization originally established at the initiative of the United Nations Development Programme in 1997. Its not-for-profit mission is to discover, develop, and deliver safe, effective, and affordable vaccines for global health. IVI’s current portfolio includes vaccines in multiple stages of pre-clinical and clinical development targeting infectious diseases that significantly impact low- and middle-income countries, including cholera, typhoid fever, chikungunya, shigellosis, salmonellosis, schistosomiasis, hepatitis E, HPV- and group A strep-related diseases, and COVID-19. IVI developed the world’s first low-cost oral cholera vaccine and a new-generation typhoid conjugate vaccine, both pre-qualified by the World Health Organization (WHO). IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, Madagascar, and Burkina Faso. More than 40 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, Austria, Finland, India, and Thailand provide state funding.